Structure-activity relationships of philanthotoxin analogs and polyamines on N-methyl-D-aspartate and nicotinic acetylcholine receptors. 1990

N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
Department of Pharmacology & Experimental Therapeutics, University of Maryland School of Medicine, Baltimore.

The effects of varying the structure of philanthotoxin (PhTX) were investigated on binding of the channel blockers: [3H]perhydrohistrionicotoxin (H12-HTX) to the nicotinic acetylcholine receptor (nACh-R) of Torpedo electric organ and [3H]MK-801 [( 3H]-5-methyl-10,11-dihydro-5H-dibenzocyclo-hepten-5,10-imine maleate) to the N-methyl-D-aspartate receptor (NMDA-R) of rat brain cortex. The four moieties of PhTX (tyrosine, butyrate, spermine and the terminal amino group) were modified or conjugated resulting in 36 compounds. Although the potencies of the PhTX analogs on both receptors were higher with increasing lipophilicity and the polyamine chain length, there was considerable divergence between the two receptors' channels in the structural activity requirements for blockade by PhTX analogs. A major difference was the more critical role of the amine terminal for inhibition of the nACh-R than the NMDA-R, whereas the reverse might be true for the tyrosine moiety. The potency range of PhTX analogs on [3H]H12-HTX binding was 1070, but only 21 on [3H]MK-801 binding. Adding a lysine or arginine onto the spermine moiety increased the compound's potency on the nACh-R with little effect on the NMDA-R. Because spermine is a component of PhTX, the effects of five polyamines were also studied. Spermine and spermidine potentiated [3H]MK-801 binding, whereas putrescine, cadeverine and agmatine inhibited it. In presence of glutamate, higher concentrations of all polyamines inhibited [3H]MK-801 binding. On the nACh-R, spermine, spermidine and agmatine inhibited [125I]alpha-bungarotoxin and also [3H]H12-HTX binding in presence of carbamylcholine. The complex nature of PhTX interactions with the two receptors suggests that PhTX may bind to two sites: an external polyamine binding site and a channel binding site.

UI MeSH Term Description Entries
D011073 Polyamines Amine compounds that consist of carbon chains or rings containing two or more primary amino groups. Polyamine
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D003986 Dibenzocycloheptenes A family of tricyclic hydrocarbons whose members include many of the commonly used tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC).
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D001514 Bee Venoms Toxins obtained from Apis mellifera (honey bee) and related species. They contain various enzymes, polypeptide toxins, and other substances, some of which are allergenic or immunogenic or both. These venoms were formerly used in rheumatism to stimulate the pituitary-adrenal system. Apis Venoms,Honeybee Venom,Honeybee Venoms,Apitoxin,Bee Venom,Venom, Bee,Venom, Honeybee,Venoms, Apis,Venoms, Bee,Venoms, Honeybee
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013570 Synaptic Membranes Cell membranes associated with synapses. Both presynaptic and postsynaptic membranes are included along with their integral or tightly associated specializations for the release or reception of transmitters. Membrane, Synaptic,Membranes, Synaptic,Synaptic Membrane

Related Publications

N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
September 2005, Toxicon : official journal of the International Society on Toxinology,
N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
January 1991, Annals of the New York Academy of Sciences,
N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
March 1995, The Journal of pharmacology and experimental therapeutics,
N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
July 2021, European journal of medicinal chemistry,
N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
August 2007, Amino acids,
N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
April 1994, Brain research,
N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
October 2003, Molecular pharmacology,
N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
December 2003, British journal of pharmacology,
N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
February 2007, Bioorganic & medicinal chemistry,
N Anis, and S Sherby, and R Goodnow, and M Niwa, and K Konno, and T Kallimopoulos, and R Bukownik, and K Nakanishi, and P Usherwood, and A Eldefrawi
March 2005, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!